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Since the COVID-19 outbreaks in China and due to the important number of infected cases 
and related deaths, various strategies have been proposed to be used to fight the pandemic in-
cluding supplements (Krajewska et al., 2020). In spite of several ongoing trials, no efficient 
drugs have been validated till now. An optimal and equilibrated immune response in infected 
individuals seems to be a promising preventive and therapeutic alternative. Actually, it has been 
suggested that besides the close relationship of Chinese populations with wildlife and related 
dietary traditions, selenium deficiency was the cause of the SARS-CoV-1 spread due to its 
involvement in viral mutations (Qureshi, 2016). Selenium deficiency was suspected to be asso-
ciated with enhanced virulence of SARS since previous studies have shown that this deficiency 
was linked to higher mutation rate and virulence of coxsackievirus B3 and influenza and po-
liovirus. Several studies showed that selenium supplementation resulted in enhanced immune 
response in adults with or without viral infections (Jayawardena et al., 2020). Furthermore, such 
supplementation was found to effectively suppress the HIV-1 viral load (Hurwitz et al., 2007). 
Indeed, selenium possesses an important antioxidant potential through its incorporation in var-
ious selenoenzymes such as glutathione peroxidase able to breakdown hydrogen peroxide 
(Medeiros-Neto and Rubio, 2016). Accordingly, selenium deficiency, which is common among 
patients with viral infections, results in an enhanced reactive oxygen species production leading 
to an increased oxidative stress which promotes a decreased immune response, promotes viral 
mutations and an increased virulence. Selenium supplementation significantly improves the 
immunocompetence of infected hosts and decreases viral mutations leading to lowered viru-
lence (Harthill, 2011). These properties of selenium led to its incorporation into a novel pa-
tented antiviral treatment called Gene-Eden-VIR/Novirin (Polansky and Lori, 2020). Further-
more, the immune boosting properties of selenium led to its incorporation into a herbal im-
muno-modulator drug used efficiently against viral respiratory diseases (Arastoo et al., 2014). 
Interestingly, it has been recently demonstrated that selenium intake was positively associated 
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with telomere length in adults (Shu et al., 2020). It would also be interesting to experimentally 
analyze the action of selenium on viral infectiveness using in vitro and in vivo animal models. 
Recently, selenium deficiency besides vitamin D deficiency was found to be characteristic 
of Korean COVID-19 patients. In fact, selenium deficiency was found in 42 of COVID-19 
patients whereas their vitamins B, folate and zinc levels were not decreased. Interestingly, se-
lenium deficiency was found in 100 of severe COVID-19 patients against 44.4 in those with 
mild COVID-19 (without pneumonia) suggesting that selenium deficiency may weaken the 
immune system and thereby result in increasing the severity of the disease (Im et al., 2020). 
Likewise, Majeed et al. (2020) found that Indian COVID-19 patients had lower selenium levels 
(69.2 ± 8.7 ng/ml) when compared to healthy individuals (79.1 ± 10.9 ng/ml). In another cross 
sectional study, Se (selenium) deficiency was found in 44.4 of COVID-19 German patients. On 
the other hand, Se deficiency was also found to be correlated with survival rates since 64.7 of 
non-survivors were deficient in Se against 39.96 of survivors (Moghaddam et al., 2020). Fur-
thermore, serum selenium levels were demonstrated to be an important predictor of survival 
among COVID-19 patients. Actually, it has been demonstrated that unimpaired Se transporter 
selenoprotein P and Zn status was predictor of high survival in COVID-19 patients suggesting 
that Se and/or Zn supplementation may be a promising approach (Heller et al., 2020). There-
fore, intervention studies are needed to investigate whether a Se supplementation may prevent 
severe complications of the COVID-19, and related death. Besides, the prognostic value of Se 
status using serum Se and SELENOP levels may be a promising alternative, especially in Se-
deficient patients.  
Hence, we suggest that patients with COVID-19 may be at higher risk for selenium defi-
ciency and, therefore, their selenium status should be assessed. Moreover, we suggest incorpo-
rating selenium supplementation to enhance their immune response and reduce the SARS-CoV-
2 virulence.  
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